PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Protalix BioTherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.56−0.06 (-2.29%)
Close on Oct 19, 2026
- Market cap
- $211.35M
- P/E (TTM)
- 11.1
- Dividend yield
- –
Protalix BioTherapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Protalix BioTherapeutics | Industry median |
|---|---|---|
| Market Cap | $206.26M | $197.05M |
| Enterprise Value | $178.84M | $106.56M |
| PE Ratio | 11.13 | 20.52 |
| PS Ratio | 2.56 | 3.93 |
| PB Ratio | 2.89 | 2.14 |
| P/TBV Ratio | 2.89 | 2.46 |
| P/FCF Ratio | 26.90 | 18.25 |
| P/OCF Ratio | 20.79 | 13.78 |
Enterprise value
| Measure | Protalix BioTherapeutics | Industry median |
|---|---|---|
| EV / Sales | 2.22 | 2.69 |
| EV / EBITDA | 7.68 | 14.86 |
| EV / EBIT | 7.68 | 19.00 |
| EV / FCF | 23.32 | 21.02 |
Income (trailing twelve months)
| Measure | Protalix BioTherapeutics | Industry median |
|---|---|---|
| Revenue | $80.62M | $57.94M |
| Gross Profit | $55.79M | $90.47M |
| Operating Income | $23.29M | -$21.44M |
| Pretax Income | $23.46M | -$14.45M |
| Net Income | $18.95M | -$22.46M |
| EBITDA | $23.29M | -$16.91M |
| EPS (Diluted) | $0.23 | -$0.83 |
Margins
| Measure | Protalix BioTherapeutics | Industry median |
|---|---|---|
| Gross Margin | 69.2% | 52.3% |
| Operating Margin | 28.9% | -44.5% |
| Pretax Margin | 29.1% | -13.0% |
| Profit Margin | 23.5% | -39.2% |
| EBITDA Margin | 28.9% | -31.3% |
| FCF Margin | 9.51% | -8.85% |
Returns
| Measure | Protalix BioTherapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | 31.2% | -53.1% |
| Return on Assets (ROA) | 20.1% | -41.0% |
| Return on Invested Capital (ROIC) | 49.5% | -32.0% |
| Return on Capital Employed (ROCE) | 29.5% | -37.8% |
Growth
| Measure | Protalix BioTherapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 30.1% | 6.01% |
| Net Income Growth (YoY) | 201.9% | -37.7% |
| EPS Growth (YoY) | 475.0% | -29.2% |
| Revenue Growth (3Y CAGR) | 3.45% | 2.25% |
| Revenue Growth (5Y CAGR) | -3.46% | 6.42% |
Balance sheet
| Measure | Protalix BioTherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $27.42M | $62.42M |
| Net Cash (Debt) | $27.42M | $15.68M |
| Net Cash Per Share | $0.34 | $0.65 |
| Equity (Book Value) | $71.40M | $48.79M |
| Book Value Per Share | $0.89 | $1.36 |
| Tangible Book Value | $71.40M | $23.06M |
| Working Capital | $60.83M | $75.77M |
Financial position
| Measure | Protalix BioTherapeutics | Industry median |
|---|---|---|
| Current Ratio | 2.94 | 3.30 |
| Quick Ratio | 1.40 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Protalix BioTherapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | $9.92M | -$12.35M |
| Capital Expenditures | -$2.26M | -$1.06M |
| Free Cash Flow | $7.67M | -$20.28M |
| FCF Per Share | $0.10 | -$0.41 |
Efficiency
| Measure | Protalix BioTherapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.85 | 0.38 |
| Inventory Turnover | 0.93 | 2.67 |
| Revenue Per Employee | $356.72K | $398.96K |
| Profits Per Employee | $83.83K | -$732.08K |
| Employee Count | 226 | 73 |
Dividends and yields
| Measure | Protalix BioTherapeutics | Industry median |
|---|---|---|
| Earnings Yield | 9.18% | -21.2% |
| FCF Yield | 3.72% | -7.64% |
Shares
| Measure | Protalix BioTherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 80,571,600 | 59,128,900 |
| Shares Change (YoY) | -5.09% | 11.1% |
| Float | 76,830,700 | 48,744,500 |
| Shares Held by Insiders | 4.64% | 11.8% |
| Shares Held by Institutions | 17.9% | 59.4% |
Taxes
| Measure | Protalix BioTherapeutics | Industry median |
|---|---|---|
| Income Tax | $4.52M | $91.50K |
| Effective Tax Rate | 19.3% | 20.6% |
Scores
| Measure | Protalix BioTherapeutics | Industry median |
|---|---|---|
| Graham Number | $2.14 | $17.36 |
| Graham Upside | -16.3% | -45.5% |
| Altman Z-Score | 5.27 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Protalix BioTherapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.